Ophthalmic Drugs Market
Ophthalmic Drugs Market Study by Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, and Anti-VEGF Drugs from 2023 to 2033
Analysis of Ophthalmic Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ophthalmic Drugs Market Outlook (2023 to 2033)
Global demand for ophthalmic drugs is predicted to increase at a CAGR of 6.6% from 2023 to 2033. The global ophthalmic drugs market is valued at US$ 38 billion in 2023 and is thus anticipated to reach US$ 72 billion by 2033-end.
The use of ophthalmic drugs for retinal disorders is anticipated increase at a CAGR of 5% during the forecast period due to the increasing patient pool acquiring retinal problems, the presence of innovative pipeline drugs, and increased financing for the development of retinal disorder treatments.
Ophthalmic drugs are prescribed for the treatment of a variety of eye-related conditions, such as age-related macular degeneration (AMD), cytomegalovirus (CMV), diabetic macular edema, color blindness, and diabetic macular edema. The conjunctiva SAC might be injected with a liquid drop preparation, an ointment, or a lotion to administer the medication. The right dosage and strength of the medication are chosen, and it is administered to the eyes in the prescribed manner.
The issue of low bioavailability of medicinal substances after application to the eyeball is the primary driver of scientists' pervasive interest in these medication forms. These drugs may be administered through contact lenses, emulsions, ointments, aqueous gels, dendrimers, or nanosuspensions. Neomycin, antibiotics, bacitracin, and polymyxin are all used in the production of ophthalmic medications, which help to slow the spread of bacterial infections in the eyes.
There is an increase in incidences of eye-related diseases, particularly in developing countries, over the past several years. Visual impairment is a global health concern harming physical and mental health. The increasing patient pool of the visually impaired is anticipated to boost demand for healthcare spending on ophthalmic drugs.
The ophthalmic drugs market is expected to rise as a result of several major factors, including a growing elderly population, an increase in the prevalence of eye ailments, technological advancements, and rising healthcare spending awareness. Market expansion is being supported by the substantial financing and supportive measures being implemented by the governments of numerous countries to stimulate the creation of efficient ophthalmic medications with novel formulations and combinations.
Additional growth-promoting elements include substantial technological developments, such as the development of gene-drug therapy for the diagnosis and treatment of hereditary ophthalmic, neurovascular retinal, and retinoblastoma problems.
Furthermore, the easy accessibility of ophthalmic medications in the forms of eye solutions, drops, capsules, pills, gels, and ointments via several online and offline distribution channels is fostering market expansion. A favorable outlook for the ophthalmic drugs market is being created by other factors such as the rapid expansion of the pharmaceutical industry and an increase in R&D operations to develop affordable ocular drug delivery systems (ODDS).
| Report Attributes | Details |
|---|---|
| Ophthalmic Drugs Market Size (2023) | US$ 38 Billion |
| Projected Market Value (2033) | US$ 72 Billion |
| Global Market Growth Rate (2023 to 2033) | 6.6% CAGR |
| Market Share of Anti-glaucoma Drugs | 60% |
| Key Companies Profiled | Alcon; Nicox S.A.; Novartis AG; Tapros; Regeneron Pharmaceuticals Inc.; ALLERGAN; Santen Pharmaceutical Co., Ltd.; Bayer AG |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Key Aspects are Shaping Ophthalmic Drug Demand across the World?
“Growing Usage of Contact Lenses and Rise in Geriatric Population”
Compared to the use of glasses, contact lens use has significantly increased in recent years. The use of contact lenses by individuals who experience dry eye conditions has led to a large rise in the need for ophthalmic medications.
Many people are suffering from age-related illnesses. The demand for pharmaceuticals used as preventative measures and for treating various ailments has increased recently, and this trend will continue during the projection period.
“Increase in Patients Suffering from Various Eye Disorders”
Demand for ophthalmic drugs is predicted to increase due to a rise in patients experiencing vision impairment. With the aid of various medications, it is possible to prevent these disorders, which will prove to be a significant opportunity for market expansion over the coming years. Surging diabetes incidence in the elderly population and the eye ailment known as diabetic retinopathy are the elements boosting sales of ophthalmic drugs.
“New Developments in Drug Delivery Techniques”
The ophthalmic drugs market is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as several strategic initiatives by the major players. Ophthalmic drugs have a considerable competitive edge over their counterparts due to their multiyear drug delivery system. Implanted contact lenses and medicines are two other innovative medication delivery methods.
The development of gene therapies as an effective means of drug delivery is one of the major factors driving this industry. Gene therapy enables the modification of patient cells to produce particular therapeutic entities using viral or non-viral vectors in both in-vitro and in-vivo settings.
Gene therapy can be used to identify and treat retinoblastoma, neurovascular retinal abnormalities, and inherited ophthalmic illnesses such as retinitis pigmentosa. Over the projection period, there should be potential for market expansion as more research is needed to advance and widen the application of gene therapy across ophthalmic illnesses.
Growing awareness of advanced treatment options for a variety of eye disorders patients and medical professionals is driving the demand for novel ophthalmic drugs. Manufacturers are also concentrating on creating advanced drug delivery systems that can increase patient compliance rates and lessen negative effects related to conventional therapies.
What Obstacles Need to Be Tackled by Suppliers of Ophthalmic Drugs?
“Lack of Skilled Professionals and Adverse Effects of Ophthalmic Medications”
Market expansion is anticipated to be constrained by the loss of patent protection for popular medications used to treat eye illnesses and the absence of health insurance in developing countries. The high cost of product development is expected to restrain market growth over the coming years, according to pricing trends.
The market for ophthalmic drugs will be challenged by the shortage of skilled professionals and the adverse effects of ophthalmic medications may impede market revenue.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Region is Predicted to Lead Market Expansion Going Forward?
“Favorable Reimbursement Policies Driving Market Growth in North America”
North America accounts for 50% share of the global market owing to the rising prevalence of eye diseases. Growing initiatives by key market players to develop innovative drugs, favorable reimbursement policies, and growing awareness of early ophthalmic disease diagnosis are supporting market expansion in the region.
Country-wise Insights
Which Country is Asserting its Dominance in North America?
“Growing Awareness among People about Accessibility of Ophthalmic Drugs”
The market is predicted to be dominated by the United States due to the increase in the prevalence of blindness, vision impairment, and other eye-related illnesses. Market growth in the United States is attributed to the growing awareness among people about the accessibility of ophthalmic drugs, increased government investments in eye health, and the availability of qualified healthcare professionals.
What is Benefitting Providers of Ophthalmic Drugs in Germany?
“Increase in Drug Approvals in the Country”
The main reason fueling the expansion of the market in Germany is improved regulatory policies, which have strengthened consumer confidence in the pharmaceutical industry. Key companie's strategic moves toward the commercialization of a few medicines, the presence of a large patient pool, increased drug approvals, and a rise in the local supply of ophthalmic drugs are boosting market value in Germany.
What is Making Japan Stand Out in the Asia Pacific Market?
“Increasing Investments by Research Institutes for Innovations in Ophthalmic Drugs”
The growing elderly population, higher healthcare spending, improved healthcare infrastructure, and a rise in consumer disposable income levels are the factors supporting market expansion in Japan. Increasing investments by research institutes for innovations in ophthalmic drugs are driving market growth in Japan.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Why are Anti-glaucoma Drugs Highly Preferred?
“Rising Pool of Glaucoma Patients Driving Sales of Anti-glaucoma Drugs”
Based on therapeutic class, the market is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF drugs, and others. Anti-glaucoma drugs account for 60% share of the global market.
Abnormally high pressure in the eye is generally the cause of glaucoma, a group of eye illnesses that impair the optic nerve, which is necessary for clear vision. A class of pharmaceuticals called anti-glaucoma ophthalmic drugs is used to reduce the pressure inside the eye. These drugs may be useful in lowering the risk of glaucoma, a disorder that can impair eyesight.
Rising geriatric population, which is more prone to developing glaucoma, and the increasing prevalence of glaucoma are the elements driving the demand for anti-glaucoma drugs. Key businesses are putting more emphasis on creating innovative medicines and products to treat glaucoma patients. This is anticipated to result in more product releases, which will fuel market expansion.
Which Product Accounts for a Leading Market Share?
“Prescription Drugs More Preferred Due to High Efficacy in Treating Ocular Conditions”
Based on product, the market is divided into prescription drugs and OTC drugs. Prescription drugs hold 50% share of the global market owing to an increase in conditions such as AMD and diabetic retinopathy. Improved safety and efficacy are two variables driving the demand for prescription drugs.
Some prescription drugs have lubricating and moisturizing ingredients that temporarily increase tear production. Prescription drugs are chosen over over-the-counter ones because they are thought to be the most effective in treating ocular conditions.
Additionally, a rising success rate for recently introduced prescription-only medicines would support market expansion. Since these medications are intended to be applied to the eyes only, patients must have a prescription before receiving ophthalmic steroids.
Competitive Landscape
Top ophthalmic drug manufacturers are focusing on supply chain management, collaborations with other companies, and enhancing quality control to gain a competitive edge in the market. Leading companies are improving product standards of new ophthalmic drugs and innovating their development formula following safety regulations to lower the environmental impact.
Major players are investing heavily in extensive R&D initiatives to increase their market share. Product portfolio expansion and mergers and acquisitions are two important techniques used by key participants.
For instance :
- Santen Pharmaceutical Co. and Singapore Eye Research Institute announced a strategic collaboration to develop new technologies for unmet medical needs in key ophthalmic drug domains. The company manufactures prescription drugs for corneal, retinal, and glaucoma diseases, which include Diquas, Tapros, Alesion, and Eylea. Novartis AG, another player, integrates new products into its existing pipeline of drugs. It specializes in innovative medicines and includes ophthalmic drug products such as Lucentis and Travoprost.
- In 2022, Novartis acquired Kedalion Therapeutics and its ground-breaking ocular delivery system, which can improve the patient experience.
Key Segments of Ophthalmic Drugs Industry Research
-
By Therapeutic Class :
- Anti-inflammatory Drugs
- NSAIDs
- Steroids
- Anti-infective Drugs
- Anti-fungal Drugs
- Anti-bacterial Drugs
- Others
- Anti-glaucoma Drugs
- Alpha Agonist
- Beta Blockers
- Prostaglandin Analogs
- Combined Medication
- Others
- Anti-allergy Drugs
- Anti-VEGF Drugs
- Others
- Anti-inflammatory Drugs
-
By Product :
- Prescription Drugs
- OTC Drugs
-
By Disease Indication :
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders
- Wet AMD
- Dry AMD
- Diabetic Retinopathy
- Others
- Allergy
- Uveitis
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies & Drug Stores
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Global Market Analysis and Forecasts, By Disease Indication
- 5.1. Dry Eye
- 5.2. Glaucoma
- 5.3. Infection/Inflammation
- 5.4. Retinal Disorders
- 5.4.1. Wet AMD
- 5.4.2. Dry AMD
- 5.4.3. Diabetic Retinopathy
- 5.4.4. Others
- 5.5. Allergy
- 5.6. Uveitis
- 5.7. Others
- 6. Global Market Analysis and Forecasts, By Therapeutic Class
- 6.1. Anti-inflammatory Drugs
- 6.1.1. NSAID
- 6.1.2. Steroids
- 6.2. Anti-infective Drugs
- 6.2.1. Anti-fungal Drugs
- 6.2.2. Anti-bacterial Drugs
- 6.2.3. Others
- 6.3. Anti-glaucoma Drugs
- 6.3.1. Alpha Agonist
- 6.3.2. Beta Blockers
- 6.3.3. Prostaglandin Analogs
- 6.3.4. Combined Medication
- 6.3.5. Others
- 6.4. Anti-allergy Drugs
- 6.5. Anti-VEGF Agents
- 6.6. Others
- 6.1. Anti-inflammatory Drugs
- 7. Global Market Analysis and Forecasts, By Product Type
- 7.1. Prescription Drugs
- 7.2. OTC Drugs
- 8. Global Market Analysis and Forecasts, By Distribution Channels
- 8.1. Hospital Pharmacies
- 8.2. Online Pharmacies
- 8.3. Independent Pharmacies & Drug Stores
- 9. Global Market Analysis and Forecasts, By Region
- 9.1. North America
- 9.2. Europe
- 9.3. Asia Pacific
- 9.4. Latin America
- 9.5. Middle East and Africa
- 10. North America Market Analysis and Forecast
- 11. Europe Market Analysis and Forecast
- 12. Asia Pacific Market Analysis and Forecast
- 13. Latin America Market Analysis and Forecast
- 14. Middle East and Africa Market Analysis and Forecast
- 15. Competition Landscape
- 15.1. Aerie Pharmaceuticals, Inc.
- 15.2. ALLERGAN
- 15.3. Valeant Pharmaceuticals International, Inc.
- 15.4. Bayer AG
- 15.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
- 15.6. Novartis AG
- 15.7. Pfizer Inc.
- 15.8. Regeneron Pharmaceuticals, Inc.
- 15.9. Santen Pharmaceutical Co., Ltd.
- 15.10. Shire
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Product Offering - Major Market Players
Table 02: Global Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 03: Global Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication - Retinal Disorder, 2023 to 2033
Table 04: Global Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 05: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023 to 2033
Table 06: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023 to 2033
Table 07: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023 to 2033
Table 08: Global Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 09: Global Market Size (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 10: Global Market Size (US$ Mn) Forecast, by Region, 2023 to 2033
Table 11: North America Market Size (US$ Mn) Forecast, by Country, 2023 to 2033
Table 12: North America Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 13: North America Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023 to 2033
Table 14: North America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 15: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023 to 2033
Table 16: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023 to 2033
Table 17: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023 to 2033
Table 18: North America Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 19: North America Market Size (US$ Mn) Forecast, by Distribution Channels, 2023 to 2033
Table 20: Europe Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023 to 2033
Table 21: Europe Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 22: Europe Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023 to 2033
Table 23: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 24: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2023 to 2033
Table 25: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2023 to 2033
Table 26: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2023 to 2033
Table 27: Europe Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 28: Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 29: Asia Pacific Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 30: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 31: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023 to 2033
Table 32: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 33: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023 to 2033
Table 34: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023 to 2033
Table 35: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023 to 2033
Table 36: Asia Pacific Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 37: Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 38: Latin America Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 39: Latin America Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 40: Latin America Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023 to 2033
Table 41: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 42: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023 to 2033
Table 43: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023 to 2033
Table 44: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023 to 2033
Table 45: Latin America Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 46: Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 47: Middle East & Africa Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023 to 2033
Table 48: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication, 2023 to 2033
Table 49: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2023 to 2033
Table 50: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023 to 2033
Table 51: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023 to 2033
Table 52: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023 to 2033
Table 53: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023 to 2033
Table 54: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2023 to 2033
Table 55: Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size (US$ Mn) Forecast, 2023 to 2033
Figure 02: Global Company Share: Anti-glaucoma Drugs, 2018
Figure 03: Global Causes of Blindness
Figure 04: U.S. - Causes of Blindness
Figure 05: Europe - Causes of Blindness
Figure 06: Japan Causes of Blindness
Figure 07: Global Market Attractiveness, by Disease Indication, 2023 to 2033
Figure 08: Global Market Value Share, by Disease Indication, 2023 and 2033
Figure 09: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2023 to 2033
Figure 10: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2023 to 2033
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2023 to 2033
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2023 to 2033
Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2023 to 2033
Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2023 to 2033
Figure 15: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2023 to 2033
Figure 16: Global Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 17: Global Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 19: Global Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 18: Global Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 20: Global Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 21: Global Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 22: Global Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 23: Global Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 24: Global Market Value Share, by Product Type, for 2023 and 2033
Figure 25: Global Market Attractiveness, by Product Type, 2023 to 2033
Figure 26: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2023 to 2033
Figure 27: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2023 to 2033
Figure 28: Global Market Value Share, by Distribution Channel, for 2023 and 2033
Figure 29: Global Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 30: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2023 to 2033
Figure 31: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2023 to 2033
Figure 32: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2023 to 2033
Figure 33: Global Market Value Share, by Region, for 2023 and 2033
Figure 34: Global Market Attractiveness, by Region, 2023 to 2033
Figure 35: North America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 36: North America Market Attractiveness, by Country, 2023 to 2033
Figure 37: North America Market Value Share, by Country, 2023 and 2033
Figure 38: North America Market Attractiveness, By Disease Indication, 2023 to 2033
Figure 39: North America Market Value Share, by Disease Indication, 2023 and 2033
Figure 40: North America Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 41: North America Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 42: North America Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 43: North America Market Attractiveness, by Product Type, 2023 to 2033
Figure 44: North America Market Value Share, by Distribution Channels, 2023 and 2033
Figure 45: North America Market Attractiveness, by Distribution Channels, 2023 to 2033
Figure 46: Europe Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 47: Europe Market Attractiveness, by Country/Sub-Region, 2023 to 2033
Figure 48: Europe Market Value Share, by Country/Sub-Region, 2023 and 2033
Figure 49: Europe Market Attractiveness, By Disease Indication, 2015-2025
Figure 50: Europe Market Value Share, by Disease Indication, 2023 and 2033
Figure 51: Europe Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 52: Europe Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 53: Europe Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 54: Europe Market Attractiveness, by Product Type, 2023 to 2033
Figure 55: Europe Market Value Share, by Distribution Channel, 2023 and 2033
Figure 56: Europe Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 57: Asia Pacific Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 58: Asia Pacific Market Attractiveness, by Country/Sub-region, 2023 to 2033
Figure 59: Asia Pacific Market Value Share, by Country/Sub-region, for 2023 and 2033
Figure 60: Asia Pacific Market Attractiveness, by Disease Indication, 2023 to 2033
Figure 61: Asia Pacific Market Value Share, by Disease Indication, for 2023 and 2033
Figure 62: Asia Pacific Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 63: Asia Pacific Market Value Share, by Therapeutic Class, for 2023 and 2033
Figure 64: Asia Pacific Market Value Share Analysis, by Product Type, for 2023 and 2033
Figure 65: Asia Pacific Market Attractiveness, by Product Type, 2023 to 2033
Figure 66: Asia Pacific Market Value Share, by Distribution Channel, for 2023 and 2033
Figure 67: Asia Pacific Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 68: Latin America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 69: Latin America Market Attractiveness, by Country/Sub-region, 2023 to 2033
Figure 70: Latin America Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 71: Latin America Market Attractiveness, by Disease Indication, 2023 to 2033
Figure 72: Latin America Market Value Share, by Disease Indication, 2023 and 2033
Figure 73: Latin America Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 74: Latin America Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 75: Latin America Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 76: Latin America Market Attractiveness, by Product Type, 2023 to 2033
Figure 77: Latin America Market Value Share, by Distribution Channel, 2023 and 2033
Figure 78: Latin America Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 79: Middle East & Africa Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023 to 2033
Figure 80: Middle East & Africa Market Attractiveness, by Country/Sub-Region, 2023 to 2033
Figure 81: Middle East & Africa Market Value Share, by Country/Sub-Region, 2023 and 2033
Figure 82: Middle East & Africa Market Attractiveness, by Disease Indication, 2023 to 2033
Figure 83: Middle East & Africa Market Value Share, by Disease Indication, 2023 and 2033
Figure 84: Middle East & Africa Market Attractiveness, by Therapeutic Class, 2023 to 2033
Figure 85: Middle East & Africa Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 86: Middle East & Africa Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 87: Middle East & Africa Market Attractiveness, by Product Type, 2023 to 2033
Figure 88: Middle East & Africa Market Value Share, by Distribution Channel, 2023 and 2033
Figure 89: Middle East & Africa Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 90: Global Market Share, by Company, 2018
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the value of the ophthalmic drugs market in 2023?
The global ophthalmic drugs market is valued at US$ 38 billion in 2023.
Which is the dominant regional market for ophthalmic drugs?
North America accounts for 50% share of the global market.
What is boosting the sales of ophthalmic drugs?
Increasing prevalence of eye diseases and growing geriatric population are driving market growth.
How big will the market for ophthalmic drugs be by 2033?
By 2033-end, the ophthalmic drugs market is expected to reach US$ 72 billion.
At what rate will ophthalmic drug demand evolve over the next ten years?
Worldwide consumption of ophthalmic drugs is estimated to rise at a CAGR of 6.6% through 2033.
Ophthalmic Drugs Market